Parallax Volatility Advisers’s Myriad Genetics MYGN Stock Holding History

Parallax Volatility Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18,200	Closed	-$502K	–	3022
2021 Q4	$502K	Buy	+18,200	New	+$527K	﹤0.01%	1453
2019 Q3	–	Sell	-17,500	Closed	-$486K	–	3060
2019 Q2	$486K	Sell	17,500 -182,500	-91%	-$5.15M	﹤0.01%	1515
2019 Q1	$6.64M	Buy	+200,000	New	+$6.09M	0.01%	601
2015 Q4	–	Sell	-20,000	Closed	-$750K	–	3535
2015 Q3	$750K	Buy	+20,000	New	+$710K	﹤0.01%	1397

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Parallax Volatility Advisers's MYGN Position: Q1 2022 in Review

Parallax Volatility Advisers sold out of Myriad Genetics (MYGN) in Q1 2022, closing a stake of 8,008 shares — an estimated $221K sold.

Parallax Volatility Advisers first reported a position in MYGN in Q3 2015 and held it in 7 quarters. The position peaked at $5.61M in Q1 2019. 205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.

Parallax Volatility Advisers reported no remaining Myriad Genetics position as of Q1 2022 after selling out during the quarter.
Parallax Volatility Advisers sold 8,008 Myriad Genetics shares in Q1 2022, an estimated $221K.
Parallax Volatility Advisers first reported a position in Myriad Genetics in Q3 2015 and held it in 7 quarters.
Parallax Volatility Advisers's Myriad Genetics position peaked at $5.61M in Q1 2019.
205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.

Based on Parallax Volatility Advisers's 13F filing for Q1 2022, filed 16 May 2022.